PURE Bioscience, Inc. balance sheet PURE

Annual Quarterly

As of Jul 31, 2026, PURE Bioscience, Inc. had total assets of $1.2 million and total liabilities of $7.6 million. Total assets were up 12.8% from a year earlier. Stockholders' equity was negative, at -$6.4 million, because liabilities exceed assets. It held $569,000 in cash and investments against $6.6 million of total debt, net debt of $6.0 million. The current ratio, current assets divided by current liabilities, was 0.27.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2026
Jul 31, 2026
FY 2025
Jul 31, 2025
FY 2024
Jul 31, 2024
FY 2023
Jul 31, 2023
FY 2022
Jul 31, 2022
FY 2021
Jul 31, 2021
FY 2020
Jul 31, 2020
FY 2019
Jul 31, 2019
FY 2018
Jul 31, 2018
FY 2017
Jul 31, 2017
Assets
Cash
1
+70.4%
0
-4.3%
0
-68.1%
1
-67.7%
3
+41.9%
2
-37.7%
4
+864.6%
0
-53.2%
1
-48.1%
2
-68.4%
Cash and investments
1
+70.4%
0
-4.3%
0
-68.1%
1
-67.7%
3
+41.9%
2
-37.7%
4
+864.6%
0
-53.2%
1
-48.1%
2
-68.4%
Receivables
0
-29.5%
0
+59.1%
0
+4.6%
0
+41.8%
0
-45.4%
0
-66.2%
1
+192.0%
0
+35.6%
0
-7.4%
0
+12.9%
Inventory
0
+36.9%
0
+151.8%
0
-36.4%
0
-50.8%
0
-46.1%
0
-39.3%
1
+209.0%
0
-10.2%
0
-27.8%
0
-22.0%
Total current assets
1
+13.2%
1
+30.1%
1
-49.8%
2
-58.5%
4
+20.9%
3
-42.6%
6
+434.7%
1
-28.5%
1
-40.8%
2
-60.0%
Property and equipment, net
0
-27.3%
0
-15.4%
0
-94.1%
0
-64.4%
1
-16.2%
1
+134.2%
0
-12.7%
0
-21.5%
0
-15.9%
1
+24.5%
Total assets
1
+12.8%
1
+29.3%
1
-55.2%
2
-59.3%
4
+4.2%
4
-31.9%
6
+227.3%
2
-25.0%
3
-32.8%
4
-49.4%
Liabilities and equity
Accounts payable
1
+4.6%
1
+30.4%
1
+42.4%
0
-13.5%
0
-17.7%
1
-55.9%
1
+143.0%
1
-9.0%
1
+42.7%
0
-11.1%
Total current liabilities
4
+106.9%
2
+188.3%
1
+37.8%
1
-7.5%
1
-40.7%
1
-35.8%
2
+104.9%
1
-42.4%
1
-49.3%
3
-0.3%
Total liabilities
8
+23.0%
6
+67.7%
4
+137.1%
2
+170.1%
1
-40.7%
1
-35.8%
2
+103.8%
1
-42.7%
1
-49.0%
3
+0.0%
Stockholders' equity
-6
-25.1%
-5
-78.6%
-3
-1152.9%
0
-93.0%
4
+17.3%
3
-30.7%
5
+304.3%
1
-7.1%
1
-0.7%
1
-74.3%
Debt
Long-term debt
7
—
—
—
—
—
—
—
—
—
Total debt
7
—
—
—
—
—
—
—
—
—
Net cash
-6
—
—
—
—
—
—
—
—
—
Ratios
Current ratio
0.27x
0.50x
1.10x
3.02x
6.72x
3.30x
3.68x
1.41x
1.14x
0.97x
Return on equity
—
—
—
-1,456.25%
-89.31%
-69.58%
0.08%
-550.76%
-580.95%
-485.50%
Return on assets
-208.13%
-226.75%
-409.54%
-217.04%
-77.85%
-53.89%
0.06%
-339.23%
-289.01%
-163.57%
Book value per share
-0.05
-0.05
-0.03
0.00
0.04
0.04
0.06
0.02
0.02
0.02
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Miscellaneous Chemical Products (SIC 2890)
Listed as
PURE (OTC)
Fiscal year ends
July 31
Incorporated in
DE
Headquarters
El Cajon, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1006028
Former names
PURE BIOSCIENCE (until Mar 17, 2011); INNOVATIVE MEDICAL SERVICES (until Sep 2, 2003)

Other Miscellaneous Chemical Products companies

All 11 Miscellaneous Chemical Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.